Heron Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.09) Per Share, Capital One Financial Forecasts (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at Capital One Financial issued their Q1 2024 EPS estimates for Heron Therapeutics in a report released on Tuesday, April 23rd. Capital One Financial analyst T. Chiang anticipates that the biotechnology company will earn ($0.09) per share for the quarter. Capital One Financial has a “Overweight” rating and a $6.00 price objective on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.22) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.28) EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $0.33 EPS and FY2028 earnings at $0.47 EPS.

Several other equities analysts have also recently weighed in on the stock. StockNews.com raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Heron Therapeutics in a research note on Thursday, April 11th.

Heron Therapeutics Price Performance

HRTX stock opened at $2.55 on Thursday. The stock has a market capitalization of $383.34 million, a PE ratio of -2.97 and a beta of 1.68. The company’s 50-day moving average is $2.75 and its 200-day moving average is $1.96. Heron Therapeutics has a 1 year low of $0.50 and a 1 year high of $3.22.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.08. The firm had revenue of $34.23 million for the quarter, compared to the consensus estimate of $30.98 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HRTX. Adage Capital Partners GP L.L.C. increased its position in shares of Heron Therapeutics by 100.0% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,060,000 after acquiring an additional 1,000,000 shares during the period. JW Asset Management LLC lifted its stake in shares of Heron Therapeutics by 9.1% in the third quarter. JW Asset Management LLC now owns 2,407,418 shares of the biotechnology company’s stock worth $2,480,000 after buying an additional 200,000 shares in the last quarter. Congress Park Capital LLC lifted its stake in shares of Heron Therapeutics by 205.3% in the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock worth $3,058,000 after buying an additional 1,209,500 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Heron Therapeutics in the third quarter worth approximately $31,000. Finally, Tejara Capital Ltd lifted its stake in shares of Heron Therapeutics by 28.6% in the third quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock worth $2,173,000 after buying an additional 469,548 shares in the last quarter. 80.01% of the stock is owned by institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.